AnaMar initiates clinical trials of oral RA drug
Swedish biotechnology company AnaMar Medical has initiated clinical trials of AMAP102, a new oral drug candidate for the treatment of rheumatoid arthritis.
The drug inhibits interleukin-6 and tumor necrosis factor alpha to prevent inflammation, and has also shown an effect on pain.
"After successful preclinical development, AMAP102 holds promise as a novel treatment for RA and is now ready to be tested in a first-in-man study," said Gunilla Ekstrom, vice president of R&D at AnaMar. "The aim of the study is to establish the safety and tolerability of the compound, as well as pharmacokinetics to support further clinical trials," the VP added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze